• Home
  • Pharmacy Medical Policy Updates

Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs were updated May 1, 2024:

Effective June 1, 2024:

  • Cibinqo
  • IL-13 Antagonist
  • IL-4 Inhibitor
  • IL-5 Inhibitors
  • Zoryve
  • IL-1 Inhibitor 
  • Lupus 
  • Xolair
  • Soliris/Ultomiris
  • Empaveli  (
  • Agamree, Emflaza (formerly Emflaza)
  • Fabhalta

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.

Institutional Providers
Professional Providers